Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 20,362 | 17,966 | 17,799 | 18,592 | 15,831 |
| TOTAL | $21,611 | $19,468 | $19,552 | $20,552 | $17,121 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 552 | 613 | 673 | 733 | 793 |
| TOTAL | $552 | $613 | $673 | $733 | $793 |
| Total Assets | $22,163 | $20,081 | $20,225 | $21,285 | $17,914 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,681 | 1,976 | 2,553 | 3,890 | 2,352 |
| Accrued Expenses | 7,841 | 7,913 | 8,980 | 9,058 | 7,236 |
| TOTAL | $10,522 | $9,953 | $11,533 | $13,012 | $9,588 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 62,514 | 61,255 | 51,338 | 40,467 | 30,661 |
| TOTAL | $62,514 | $61,255 | $51,338 | $40,467 | $30,661 |
| Total Liabilities | $73,036 | $71,208 | $62,871 | $53,479 | $40,249 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 61,849 | 59,582 | 59,582 | 59,444 | 59,426 |
| Common Shares | 61 | 59 | 59 | 59 | 59 |
| Retained earnings | -344,312 | -330,271 | -321,094 | -309,567 | -298,868 |
| Other shareholders' equity | 2,233 | 2,233 | 2,233 | 2,233 | 2,233 |
| TOTAL | $-50,873 | $-51,127 | $-42,646 | $-32,194 | $-22,335 |
| Total Liabilities And Equity | $22,163 | $20,081 | $20,225 | $21,285 | $17,914 |